Girentuximab
Girentuximab
Girentuximab (pronounced: gi-ren-tux-i-mab) is a monoclonal antibody designed for the treatment of renal cell carcinoma, a type of kidney cancer. It is a type of immunotherapy that targets carbonic anhydrase IX (CAIX), a protein that is overexpressed in renal cell carcinoma.
Etymology
The name "Girentuximab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The prefix "Giren-" is randomly assigned, "-tuxi-" indicates that it targets tumors, and "-mab" denotes that it is a monoclonal antibody.
Mechanism of Action
Girentuximab works by binding to the CAIX protein on the surface of renal cell carcinoma cells. This binding triggers an immune response that leads to the destruction of the cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Renal cell carcinoma: The most common type of kidney cancer in adults.
- Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
- Carbonic anhydrase IX (CAIX): A protein that is overexpressed in renal cell carcinoma and is the target of Girentuximab.
See Also
External links
- Medical encyclopedia article on Girentuximab
- Wikipedia's article - Girentuximab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski